UY34812A - Método para el tratamiento del cáncer de pulmón de células no pequeñas - Google Patents

Método para el tratamiento del cáncer de pulmón de células no pequeñas

Info

Publication number
UY34812A
UY34812A UY0001034812A UY34812A UY34812A UY 34812 A UY34812 A UY 34812A UY 0001034812 A UY0001034812 A UY 0001034812A UY 34812 A UY34812 A UY 34812A UY 34812 A UY34812 A UY 34812A
Authority
UY
Uruguay
Prior art keywords
treatment
lung cancer
small cells
cells
small
Prior art date
Application number
UY0001034812A
Other languages
English (en)
Spanish (es)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34812A publication Critical patent/UY34812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UY0001034812A 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas UY34812A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
UY34812A true UY34812A (es) 2013-12-31

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034812A UY34812A (es) 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas

Country Status (17)

Country Link
US (1) US20130310440A1 (cg-RX-API-DMAC7.html)
EP (1) EP2849761A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015522542A (cg-RX-API-DMAC7.html)
KR (1) KR20150024843A (cg-RX-API-DMAC7.html)
CN (1) CN104684564A (cg-RX-API-DMAC7.html)
AR (1) AR091090A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013262589A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014028787A2 (cg-RX-API-DMAC7.html)
CA (1) CA2874092A1 (cg-RX-API-DMAC7.html)
EA (1) EA201492148A1 (cg-RX-API-DMAC7.html)
IL (1) IL235459A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10390A (cg-RX-API-DMAC7.html)
PH (1) PH12014502569A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201407649RA (cg-RX-API-DMAC7.html)
TW (1) TW201402132A (cg-RX-API-DMAC7.html)
UY (1) UY34812A (cg-RX-API-DMAC7.html)
WO (1) WO2013173757A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227190B1 (en) 1999-02-26 2010-10-28 Univ British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
BR122021016044B1 (pt) 2010-05-08 2022-07-19 Bruin Biometrics, Llc Aparelho para detecção de umidade subepidérmica (sem)
MX2013010524A (es) 2011-03-15 2013-12-06 Univ British Columbia Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
US11304652B2 (en) 2017-02-03 2022-04-19 Bbi Medical Innovations, Llc Measurement of tissue viability
DK3515306T3 (da) 2017-02-03 2025-01-27 Bbi Medical Innovations Llc Måling af modtagelighed for diabetiske fodsår
EP4162868A1 (en) 2017-02-03 2023-04-12 Bruin Biometrics, LLC Measurement of edema
AU2018368707B2 (en) 2017-11-16 2024-03-07 Bruin Biometrics, Llc Strategic treatment of pressure ulcer using sub-epidermal moisture values
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
HUE066478T2 (hu) 2018-02-09 2024-08-28 Bruin Biometrics Llc Szöveti károsodás észlelése
IL319197A (en) 2018-10-11 2025-04-01 Bruin Biometrics Llc Device with a single-use component
MX2023009108A (es) 2021-02-03 2023-08-09 Bruin Biometrics Llc Métodos de tratamiento de daño tisular inducido por presión en estadio profundo y temprano.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP2300825A4 (en) * 2008-06-18 2012-04-25 Abbott Lab P / GF 1 COMPARATIVE DIAGNOSTIC PROCEDURES AND PRODUCTS
SG194931A1 (en) * 2011-05-19 2013-12-30 Teva Pharma Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
US20130310440A1 (en) 2013-11-21
CN104684564A (zh) 2015-06-03
SG11201407649RA (en) 2014-12-30
WO2013173757A8 (en) 2015-04-30
AU2013262589A1 (en) 2015-01-22
AR091090A1 (es) 2014-12-30
IL235459A0 (en) 2014-12-31
KR20150024843A (ko) 2015-03-09
WO2013173757A1 (en) 2013-11-21
TW201402132A (zh) 2014-01-16
BR112014028787A2 (pt) 2017-06-27
IN2014DN10390A (cg-RX-API-DMAC7.html) 2015-08-14
CA2874092A1 (en) 2013-11-21
EA201492148A1 (ru) 2015-04-30
EP2849761A1 (en) 2015-03-25
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
IL288181A (en) Cancer treatment methods
IL289300A (en) Combination therapy for treating cancer
IL272905A (en) Methods of treating pancreatic cancer
IL236336A0 (en) Methods of treating breast cancer with gemcitabine therapy
IL237791A0 (en) A method for treating cancer
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
PL3454346T3 (pl) APARAT DO CYKLOTRONOWEGO WYTWARZANIA TECHNETU-99m
LT2885010T (lt) Tautopatijos gydymo būdai
SG11201605585SA (en) Targeted therapy for small cell lung cancer
HUE048876T2 (hu) Rákos megbetegedések kezelése
BR112014032105A2 (pt) método para o tratamento de câncer
PL2739153T3 (pl) Leczenie raka sutka
EP2908843A4 (en) METHOD FOR TREATING CARCINOMA
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
EP2892536A4 (en) METHOD FOR TREATING LEUKEMIA
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
IL240688A0 (en) Pancreatic cancer treatment methods
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
BR112014027219A2 (pt) método
UY34604A (es) Inhibidores de oxadiazol de la producción de leucotrienos para terapia de combinación
EP2819706A4 (en) TARGETED TREATMENT OF ANAEROBIC CARCINOMA
EP3252171B8 (en) Methods of treating cancer
UY34277A (es) Metodo para la eliminación del naftaleno

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528